Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACM-008
- Development stage
- Preclinical
- Lead developer
- ACM Biolabs
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
ACM-008 is a preclinical-stage, lung-targeted small molecule chemotherapeutic agent being developed by ACM Biolabs. The drug utilizes the company's proprietary Artificial Cell Membrane (ACM) technology, which employs polymer-based vesicles (polymersomes) to encapsulate and deliver therapeutic payloads. ACM-008 is specifically designed to concentrate the chemotherapeutic effect within lung tissue, potentially enhancing efficacy against lung cancer while minimizing systemic side effects associated with conventional chemotherapy. The specific small molecule chemotherapeutic agent encapsulated in ACM-008 has not been publicly disclosed.
Beyond the preview
Go deeper on ACM-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM-008.